Apellis Pharmaceuticals Stock Investor Sentiment
| APLS Stock | USD 17.96 0.47 2.69% |
Slightly above 69 percent of all Apellis Pharmaceuticals' private investors are curious in acquiring. The analysis of the overall investor sentiment regarding Apellis Pharmaceuticals suggests that a large number of traders are confidant. Apellis Pharmaceuticals' investing sentiment can be driven by a variety of factors including economic data, Apellis Pharmaceuticals' earnings reports, geopolitical events, and overall market trends.
Comfort Level 69
Interested
Panic | Confidence |
Today, several news technology companies offer sentiment data to assist traders in manufacturing news sentiment indicators for investment decisions. We partner with these technology firms in helping retail investors build forecasting models that use Apellis Pharmaceuticals' input sentiment indicators derived from textual data and news published on major financial information outlets and social sites. These indicators can be used to analyze time-dependent numerical information representing public perception toward Apellis Pharmaceuticals.
News SentimentBullish | Hype SentimentBullish | Insider SentimentDisposing |
Apellis Historical Sentiment
Although Apellis Pharmaceuticals' investment sentiment alone cannot always predict changes in its future share prices, when combined with other fundamental and technical analysis, a better chance to time the market can be gained. Certain informational and emotional events regarding Apellis, such as negative comments on social media and news outlets, may cause fear in the market and push Apellis Pharmaceuticals' investors to sell their holdings. The opposite can also be true when favorable news is released; it may translate into optimism and boost the price of Apellis.
Apellis Pharmaceuticals Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Apellis Pharmaceuticals can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Apellis Pharmaceuticals Historical Investor Sentiment
Investor biases related to Apellis Pharmaceuticals' public news can be used to forecast risks associated with an investment in Apellis. The trend in average sentiment can be used to explain how an investor holding Apellis can time the market purely based on public headlines and social activities around Apellis Pharmaceuticals. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Apellis Pharmaceuticals' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Apellis Pharmaceuticals and other traded tickers. The bigger the bubble, the more accurate the estimated score. Higher bars for a given day show more participation in the average Apellis Pharmaceuticals news discussions. The higher the estimate score, the more favorable the investor's outlook on Apellis Pharmaceuticals.
Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of Apellis Pharmaceuticals' Stock prices. Below is the latest headlines and news related to Apellis Pharmaceuticals Stock. The global stock market is bullish. About 68% of major world exchanges and indexes are currently up. See today's market update for more information.
There is far too much social signal, news, headlines, and media speculation about Apellis Pharmaceuticals that are available to investors today. This information is accessible both publicly - through Apellis Pharmaceuticals' media outlets and privately, via word of mouth or internal channels. However, regardless of the source, the sheer volume of Apellis-related data is difficult to distill into actionable insights, especially for investors who are not well-versed in the rapidly evolving tools and techniques of investment management.
A primary focus of Apellis Pharmaceuticals news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Apellis Pharmaceuticals relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Apellis Pharmaceuticals' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Apellis Pharmaceuticals alpha.
Apellis Largest EPS Surprises
Earnings surprises can significantly impact Apellis Pharmaceuticals' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2024-08-01 | 2024-06-30 | -0.32 | -0.28 | 0.04 | 12 | ||
2024-05-07 | 2024-03-31 | -0.47 | -0.42 | 0.05 | 10 | ||
2018-04-30 | 2018-03-31 | -0.33 | -0.43 | -0.1 | 30 | ||
2025-02-25 | 2024-12-31 | -0.4019 | -0.29 | 0.1119 | 27 | ||
2018-03-19 | 2017-12-31 | -0.48 | -0.6 | -0.12 | 25 | ||
2018-07-31 | 2018-06-30 | -0.47 | -0.61 | -0.14 | 29 |
There is far too much social signal, news, headlines, and media speculation about Apellis Pharmaceuticals that are available to investors today. This information is accessible both publicly - through Apellis Pharmaceuticals' media outlets and privately, via word of mouth or internal channels. However, regardless of the source, the sheer volume of Apellis-related data is difficult to distill into actionable insights, especially for investors who are not well-versed in the rapidly evolving tools and techniques of investment management.
A primary focus of Apellis Pharmaceuticals news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Apellis Pharmaceuticals relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Apellis Pharmaceuticals' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Apellis Pharmaceuticals alpha.
Apellis Pharmaceuticals Performance against Dow Jones
Price Growth (%) |
| Timeline |
1 | Apellis Pharmaceuticals to Host Conference Call on February 28, 2025, to Discuss Fourth Quarter and Full Year 2024 Financial Results | 02/14/2025 |
2 | Compared to Estimates, Apellis Pharmaceuticals Q4 Earnings A Look at Key Metrics | 02/28/2025 |
3 | Disposition of 6667 shares by Watson David O. of Apellis Pharmaceuticals subject to Rule 16b-3 | 03/04/2025 |
4 | Disposition of 183 shares by Chopas James George of Apellis Pharmaceuticals at 24.8237 subject to Rule 16b-3 | 03/17/2025 |
5 | Apellis Pharmaceuticals Sets New 52-Week Low Heres What Happened | 03/31/2025 |
6 | Apellis Announces FDA Acceptance and Priority Review of the Supplemental New Drug Application for EMPAVELI for C3G and Primary IC-MPGN | 04/01/2025 |
7 | SHAREHOLDER ALERT Potential Recovery for Apellis Pharmaceuticals, Inc. Investors Affected by Stock Drop - Levi Korsinsky Pursuing Class Action Lawsuit - ACCESS ... | 04/03/2025 |
8 | ADAR1 Capital Management LLC Has 479,000 Position in Apellis Pharmaceuticals, Inc. | 04/07/2025 |
9 | BioHarvest Sciences Inc. Soars 5.2 percent Is Further Upside Left in the Stock | 04/15/2025 |
10 | Insider Trading | 04/17/2025 |
11 | Apellis Pharmaceuticals Welcomes Craig Wheeler to Board of Directors APLS Stock News | 04/21/2025 |
12 | Is Apellis Pharmaceuticals, Inc. Among the Best Guru Stocks to Buy According to Wall Street Analysts | 04/23/2025 |
Additional Tools for Apellis Stock Analysis
When running Apellis Pharmaceuticals' price analysis, check to measure Apellis Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Apellis Pharmaceuticals is operating at the current time. Most of Apellis Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Apellis Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Apellis Pharmaceuticals' price. Additionally, you may evaluate how the addition of Apellis Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.